Salute e Benessere
Amber Implants Secures FDA 510(k) Clearance for VCFix® Spinal System: A Next-Generation Solution for Vertebral Compression Fractures
One-year follow-up data from initial clinical trials of the VCFix® Spinal System, announced in June 2025 , demonstrated immediate and sustained reduction in pain, improved spinal stability, and faster recovery, underscoring its potential for lasting functional benefits. Amber Implants is also working towards CE marking in the EU, aiming for broad labeling that supports both stand-alone use of VCFix®, and integration with posterior fixation systems.
: "
Each year, more than 9 million people worldwide suffer vertebral compression fractures, including around 2 million across North America and Europe . Despite this high prevalence, up to two-thirds of cases remain undiagnosed and undertreated, leaving elderly and frail patients—most often with osteoporosis—at risk of chronic pain, spinal deformity, disability, and loss of independence. Current treatment options are limited: kyphoplasty is minimally invasive but fails to provide posterior support for fractures, while posterior fixation is invasive, restricts motion, and prolongs recovery with higher morbidity. The VCFix® Spinal System addresses these gaps as a minimally invasive solution that uniquely supports both anterior and posterior columns, integrates seamlessly into existing surgical workflows, and delivers greater stability with less patient risk.
, added:
Amber Implants is now a commercial stage company, preparing for its US launch in 2026. Supported by strong worldwide patent protection and a growing product pipeline, the Company is on track to capture a significant share of the global €2 billion+ vertebral compression fracture market by 2029. FDA clearance of the VCFix® Spinal System not only accelerates adoption and revenue growth but also serves as a gateway for entry into additional global markets where FDA approval is recognized.
Amber Implants is a commercial-stage medical technology company with operations in the Netherlands and the US. Founded in 2018, the Company develops next-generation implants for spinal injuries with the goal of improving patient outcomes through more natural healing and enhanced spinal stability. Its flagship product, the VCFix® Spinal System, offers a simpler, more efficient, and safer approach for managing a broad range of spinal fractures.
Amber Implants is financed by the Founders and venture capital investors, with participation from angel investors and non-dilutive government funding. In June 2025 , the Company reported one-year follow-up data for the VCFix® Spinal System from its first-in-human trial showing significant improvements in key clinical performance outcomes, and the device received FDA 510(k) Clearance from the US Food and Drug Administration (FDA) in September 2025.
View original content:https://www.prnewswire.co.uk/news-releases/amber-implants-secures-fda-510k-clearance-for-vcfix-spinal-system-a-next-generation-solution-for-vertebral-compression-fractures-302558332.html